Publications by authors named "E Fuzzi"
Article Synopsis
- Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE), requiring invasive kidney biopsies for diagnosis; researchers are exploring non-invasive urine biomarkers to help in this process.
- This study focused on urinary galectin-3 binding protein (u-Gal-3BP) levels in 270 subjects, including LN patients and controls, finding elevated levels in LN which correlated with disease activity.
- The results suggest that u-Gal-3BP could be a useful biomarker for diagnosing and monitoring LN, especially in certain forms of the disease, although other markers like KIM-1 also showed potential for distinguishing LN from other conditions.
Purpose Of Review: This review summarizes the recent developments about anti-MDA5 antibody positive dermatomyositis with a focus on its pathogenesis, clinical features and treatment options of rapidly progressive interstitial lung disease, its most ominous complication.
Recent Findings: Anti-MDA5+ dermatomyositis has a heterogeneous clinical spectrum with different patient subsets exhibiting widely different outcomes; severe acute interstitial lung disease is the main factor impacting prognosis. The pathogenetic role of anti-MDA5 antibodies is an active area of investigation.
Treat-to-target (T2T) is currently the most fashionable strategy for treatment-naïve, early rheumatoid arthritis (RA) patients. A T2T approach can lead to a complete and drug-free disease remission, whereas failure to obtain remission leads to damage early in the disease course. Hence, one should try to achieve high remission rates as early as possible, implementing the best therapeutic strategies available.
View Article and Find Full Text PDFObjectives: Whether immunosuppressive therapy may be safely withdrawn in lupus nephritis (LN) is still unclear. We assessed rate and predictors of flare after IS withdrawal in patients with LN in remission.
Methods: Patients with biopsy-proven LN treated with immunosuppressants (IS) between 1980 and 2020 were considered.